Show simple item record

dc.contributor.authorValle, Juan W
dc.contributor.authorWasan, H
dc.contributor.authorLopes, A
dc.contributor.authorBacken, Alison C
dc.contributor.authorPalmer, D
dc.contributor.authorMorris, Karen
dc.contributor.authorDuggan, M
dc.contributor.authorCunningham, D
dc.contributor.authorAnthoney, D
dc.contributor.authorCorrie, P
dc.contributor.authorMadhusudan, S
dc.contributor.authorMaraveyas, A
dc.contributor.authorRoss, P
dc.contributor.authorWaters, J
dc.contributor.authorSteward, W
dc.contributor.authorRees, C
dc.contributor.authorBeare, S
dc.contributor.authorDive, Caroline
dc.contributor.authorBridgewater, J
dc.date.accessioned2015-08-10T10:41:39Zen
dc.date.available2015-08-10T10:41:39Zen
dc.date.issued2015-08en
dc.identifier.citationCediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. 2015, 16 (8):967-78 Lancet Oncolen
dc.identifier.issn1474-5488en
dc.identifier.pmid26179201en
dc.identifier.doi10.1016/S1470-2045(15)00139-4en
dc.identifier.urihttp://hdl.handle.net/10541/565777en
dc.description.abstractCisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors is associated with adverse outcomes. We aimed to assess the effect of the addition of cediranib (an oral inhibitor of VEGF receptor 1, 2, and 3) to cisplatin and gemcitabine on progression-free survival.
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titleCediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.en
dc.typeArticleen
dc.contributor.departmentInstitute of Cancer Studies, University of Manchester, Manchester, UKen
dc.identifier.journalThe Lancet. Oncologyen
html.description.abstractCisplatin and gemcitabine is the standard first-line chemotherapy regimen for patients with advanced biliary tract cancer; expression of VEGF and its receptors is associated with adverse outcomes. We aimed to assess the effect of the addition of cediranib (an oral inhibitor of VEGF receptor 1, 2, and 3) to cisplatin and gemcitabine on progression-free survival.


Files in this item

This item appears in the following Collection(s)

Show simple item record